News

The basic and enantiomer patents were challenged by generics manufacturer Ranbaxy. The court ruled that the basic patent, which expires in November 2011, would be infringed by Ranbaxy’s

Scripps Translational Science Institute’s (STSI) genomic researchers are now looking to America’s healthy elderly, known as the wellderly – those 80 years and older with no history of

Mr Lloyd-Smith assumes the role previously held by Malvina Laudicina, who resigned from the company for medical reasons. Mr Lloyd-Smith joins Cadence from Elan Pharmaceuticals, where he was

According to the company, an intangible asset impairment charge of approximately $235 million, which reflects the full amount allocated to this project, will be taken in the third

This non-exclusive agreement is said to be a key component of a larger strategic initiative by Guava Technologies. The initiative is a direct response to a voiced need

The decision allows FDA-approved generic versions of immediate-release galantamine hydrobromide to enter the US marketplace ‘at risk’ pending an appeal. A favorable ruling would have provided patent protection

The FDA has requested that the company make modifications to the submitted risk management program. All aspects of the review were complete and no deficiencies were noted in

The study investigated the effects of ALSE-100 on osteoblast and osteoclast cells in culture as well as in an organ culture system. ALSE-100 stimulated differentiation and mineralization to

In this role, Mr King-Shaw will be responsible for leading the companies’s strategic growth while addressing changing market conditions and patient demand. Raul Rodriguez, who founded both companies,